Alveogene

Many serious lung conditions are caused by genetic mutations – yet current treatments are ineffective, only manage symptoms or require chronic treatment.

Alveogene is developing inhaled gene therapies that target the genetic causes of respiratory diseases, including alpha-1 antitrypsin deficiency and surfactant deficiencies. Its InGenuiTy® platform is a first-in-class Lentiviral platform that delivers treatment directly to the lungs, offering a non-invasive, targeted approach in a single dose. It’s potentially life-saving for patients who currently have no effective options.

With support provided by the Oxford-Harrington Rare Disease Centre, Alveogene brings together leading expertise from Oxford, Imperial, and Edinburgh to help more people breathe freely.